Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in dermatology.

Nina Y Wines1, Alan J Cooper, Michael P Wines

  • 1Department of Dermatology, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia. ninaandmichaelwines@telstra.com

The Australasian Journal of Dermatology
|November 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mesopotamian ancient DNA reveals Iron Age integration of heterogeneous Bronze Age genetic ancestries following resettlement.

Genome biology·2026
Same author

Australian surgical revision rate for benign prostatic obstruction.

BJU international·2023
Same author

The effect of different assays on prostate-specific antigen testing.

BJU international·2023
Same author

Identification of HIV transmitting CD11c<sup>+</sup> human epidermal dendritic cells.

Nature communications·2019
Same author

Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies?

Journal of clinical pathology·2018
Same author

Atopic dermatitis: the new frontier.

The Medical journal of Australia·2017
Same journal

Dupilumab-Associated Erythema Multiforme-Like Eruption With Lichenoid Histology in a Paediatric Patient: A Case Report.

The Australasian journal of dermatology·2026
Same journal

Contact Allergens Relevant to LGBTQI Populations: A Narrative Review and Practical Considerations.

The Australasian journal of dermatology·2026
Same journal

A Retrospective Review of Scabies Cases Managed by the Dermatology Department in a North Queensland Hospital Over a 10-Month Period.

The Australasian journal of dermatology·2026
Same journal

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study.

The Australasian journal of dermatology·2026
Same journal

Allergic Contact Dermatitis Caused by Online-Purchased Black Henna Temporary Tattoos.

The Australasian journal of dermatology·2026
Same journal

Alpelisib for TEK- and PIK3CA-Related Venous Malformations: A Systematic Review.

The Australasian journal of dermatology·2026
See all related articles

Thalidomide effectively treats over 25 inflammatory and autoimmune skin conditions. However, severe side effects like birth defects and nerve damage necessitate careful use and quality assurance, especially in Australia.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Thalidomide is a potent therapeutic agent for numerous dermatological conditions with inflammatory or autoimmune origins.
  • Significant side effects, including teratogenesis and peripheral neuropathy, restrict its clinical application.
  • Concerns exist regarding the quality, safety, and efficacy assurance of thalidomide in Australia.

Purpose of the Study:

  • To review the therapeutic indications of thalidomide in dermatology.
  • To elucidate the mechanisms of action and adverse effects associated with thalidomide.
  • To discuss current clinical practice guidelines for thalidomide use in Australia.

Main Methods:

  • Literature review of thalidomide's therapeutic uses in dermatology.

Related Experiment Videos

  • Analysis of reported mechanisms of action and side effects.
  • Examination of existing clinical guidelines and safety considerations in Australia.

    • Main Results:

    • Thalidomide demonstrates efficacy across more than 25 dermatological conditions.
    • Potential for increased mortality when used for toxic epidermal necrolysis.
    • Controversy surrounds its prophylactic use in preventing chronic graft-versus-host disease post-bone marrow transplantation.

    Conclusions:

    • Thalidomide remains a valuable, albeit risky, treatment option for specific dermatological diseases.
    • Strict adherence to safety protocols and quality control is crucial for its responsible use.
    • Further evaluation of its risk-benefit profile and updated clinical guidelines are warranted in Australia.